Research Analysts Set Expectations for SGMO FY2024 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Sangamo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($0.43) per share for the year, down from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q3 2025 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analysts’ expectations of $26.55 million. During the same period in the prior year, the firm earned ($0.34) earnings per share.

Several other analysts have also recently issued reports on SGMO. Barclays increased their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday. StockNews.com upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday.

Sangamo Therapeutics Trading Down 4.7 %

Shares of NASDAQ SGMO opened at $2.05 on Monday. The stock has a market cap of $427.73 million, a P/E ratio of -2.73 and a beta of 1.10. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The business’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $0.87.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Meritage Portfolio Management raised its stake in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after purchasing an additional 57,125 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.